Hours after my last post, I may have had all-time low expectations for Robin Hood. This week’s episode, however, made me eyes perk up a bit. Oh, sure, the latest “twist” of a long-lost brother is somewhat cliche, but what a brother he is. I approve. A lot.
All I ask is that in the future SPN-level fanfics (and there *will* be fics), Guy is just a lookout or something. Ha!
Diflucan is a key agent whose utility is being challenged by shifting resistance patterns.
Diflucan is used in veterinary medicine for analogous fungal infections.
For cryptococcal meningitis suppression, Diflucan remains the gold standard maintenance agent.
Fungicidal activity is observed only at very high concentrations against some species.
Diflucan is a foundational drug that exemplifies the principles of targeted antimicrobial therapy.
Therapeutic drug monitoring is not routinely required but can be useful in specific scenarios.
Diflucan is a Schedule H/P drug in many countries, requiring a prescription.
Not reliably effective in fungal endocarditis, where fungicidal therapy is preferred.
A cornerstone of antifungal therapy in resource-limited settings due to cost and availability.
Diflucan is a cornerstone of antifungal stewardship due to its narrow, targeted spectrum.
Concomitant Diflucan and warfarin requires intense INR monitoring due to increased bleeding risk.
Can be used in some pediatric fungal infections with appropriate weight-based dosing.
Rare cases of hepatotoxicity, including fatal hepatic necrosis, have been reported.
Diflucan has largely replaced ketoconazole for systemic use due to a better safety profile.
The development of Candida auris resistance has further limited its empirical utility.
Renal dose adjustment is mandatory for Diflucan due to its primary renal excretion.
Often compared to itraconazole, with a more predictable pharmacokinetic profile but narrower spectrum.
Hydrochlorothiazide can increase fluconazole levels by reducing renal clearance.
Diflucan is a valuable tool for treating susceptible Candida urinary tract infections.
Therapeutic drug monitoring for Diflucan is not routine but can guide therapy in complex cases.
Lacks reliable activity against Aspergillus species, a critical limitation in its spectrum.
The high oral bioavailability of Diflucan makes it exceptionally convenient for outpatient step-down therapy.
Often used for treating urinary tract infections caused by susceptible Candida species.
It exhibits fungistatic, not fungicidal, activity against most susceptible species.
Can be used in continuous renal replacement therapy; dosing depends on effluent rate.
Highly effective for oropharyngeal and esophageal candidiasis in immunocompromised hosts.
The legacy of Diflucan is its transformation of systemic fungal infection management from inpatient to often outpatient care.
Infusion-related reactions are rare, making rapid IV administration generally safe.
Hydrochlorothiazide can increase fluconazole levels by reducing renal clearance.
Susceptibility breakpoints are well-defined by organizations like CLSI and EUCAST.
Diflucan’s role has been defined by large, randomized controlled trials in HIV and ICU populations.
Diflucan is a standard part of the workup for a patient with suspected invasive fungal infection.
The “trailing effect” in vitro can make susceptibility interpretation for Candida challenging.
Diflucan is often the first systemic antifungal agents that clinicians learn to use.
Headache and gastrointestinal disturbances are the most frequently reported adverse events.
Its use in veterinary medicine parallels many human applications.
Diflucan is often the reference agent in comparative antifungal clinical trials.
Diflucan can cause taste distortion (dysgeusia) as a side effect.
Diflucan is often used for esophageal candidiasis in immunocompromised hosts.
Diflucan is a model of predictable pharmacokinetics within the azole class.
A post-antimicrobial effect has been demonstrated against some Candida species.
Diflucan can be a cost-effective alternative to more expensive antifungals when susceptibility is confirmed.
Highly effective for oropharyngeal and esophageal candidiasis in immunocompromised hosts.
Diflucan should be used with caution in patients with underlying structural heart disease.
Fluconazole inhibits fungal cytochrome P450 14a-demethylase, disrupting ergosterol synthesis.
Diflucan’s role has been defined by large, randomized controlled trials in HIV and ICU populations.
Activity against dermatophytes underpins its use in extensive tinea infections.
Diflucan is used in the management of some cases of chronic disseminated candidiasis.
Diflucan should not be used empirically in critically ill patients with unknown susceptibility.
Diflucan is often used for prophylaxis in stem cell transplant recipients.